Tirofiban in Suspected Left Ventricular Assist Device Pump Thrombosis

Area of Science:

• Cardiology
• Pharmacology

Background:

• Glycoprotein IIb/IIIa inhibitors are used for antithrombotic optimization.
• Limited literature exists on tirofiban's use for pump thrombosis.

Purpose of the Study:

• To describe the efficacy and safety of tirofiban for suspected pump thrombosis in left ventricular assist device patients.

Main Methods:

• Single-center cohort study of 14 left ventricular assist device patients treated with tirofiban.
• Tirofiban initiated at 0.1 μg/kg/min with dose adjustments for renal function or bleeding history.
• Success defined by lactate dehydrogenase normalization to baseline.

Main Results:

• 16 instances of tirofiban use were analyzed.
• Successful treatment was achieved in 12 instances (75%).
• Seven bleeding events occurred (2 major, 5 minor).

Conclusions:

• Tirofiban demonstrated a majority success rate in treating suspected pump thrombosis.
• It represents a potential therapeutic medical management option for select patients.